ACRX Stock Price, AcelRx Pharmaceuticals Quote, Chart

Market Summary

USD0.960.00

Market Closed

0.00%

ACRX Stock Price

View Fullscreen

ACRX RSI Chart

ACRX Valuation

Market Cap

16.3M

Price/Earnings (Trailing)

-0.89

Price/Sales (Trailing)

0.22

EV/EBITDA

-1.07

Price/Free Cashflow

-0.93

ACRX Price/Sales (Trailing)

ACRX Profitability

EBT Margin

70.36%

Return on Equity

-130.43%

Return on Assets

-90.2%

Free Cashflow Yield

-107.99%

ACRX Fundamentals

ACRX Revenue

ACRX Earnings

Earnings (TTM)

-18.4M

Earnings Growth (Yr)

39.64%

Earnings Growth (Qtr)

-232.87%

Breaking Down ACRX Revenue

Last 7 days

-4.9%

Last 30 days

-17.2%

Last 90 days

-7.7%

Trailing 12 Months

40.5%

How does ACRX drawdown profile look like?

ACRX Financial Health

Current Ratio

2.56

ACRX Investor Care

Shares Dilution (1Y)

127.57%

Diluted EPS (TTM)

-1.65

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	89.6M	0	0	0
2022	23.1M	43.4M	63.7M	84.1M
2021	5.5M	3.1M	3.6M	2.8M
2020	2.2M	4.2M	5.0M	5.4M
2019	2.4M	2.6M	2.8M	2.5M
2018	5.2M	3.4M	2.3M	2.2M
2017	17.4M	15.6M	13.7M	8.0M
2016	22.1M	24.7M	12.7M	17.4M
2015	8.7M	12.2M	15.8M	19.3M
2014	23.4M	17.4M	11.3M	5.2M
2013	3.0M	3.2M	3.6M	29.5M
2012	1.4M	1.7M	2.1M	2.4M
2011	0	0	0	1.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of AcelRx Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 13, 2023	angotti vincent j.	bought	7,268	0.7268	10,000	chief executive officer
Oct 10, 2023	hoffman stephen j	acquired	-	-	581	-
Oct 10, 2023	afable richard	acquired	-	-	581	-
Oct 10, 2023	adams adrian	acquired	-	-	581	-
Oct 10, 2023	broadfoot jill marie	acquired	-	-	581	-
Oct 10, 2023	rosen howard b	acquired	-	-	581	-
Oct 10, 2023	wan mark a	acquired	-	-	581	-
Oct 10, 2023	bozilenko marina	acquired	-	-	581	-
Sep 11, 2023	angotti vincent j.	bought	7,950	0.795	10,000	chief executive officer
Aug 25, 2023	palmer pamela p	sold	-8,104	1.089	-7,442	chief medical officer

Which funds bought or sold ACRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	Values First Advisors, Inc.	reduced	-16.14	17,417	116,817	0.07%
Apr 23, 2024	Global Retirement Partners, LLC	added	217	57.00	75.00	-%
Mar 28, 2024	Newbridge Financial Services Group, Inc.	sold off	-100	-73.00	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	3.09	30,531	130,170	-%
Feb 26, 2024	Virtu Financial LLC	added	156	33,000	48,000	-%
Feb 15, 2024	JANE STREET GROUP, LLC	reduced	-21.24	-18.00	8,982	-%
Feb 15, 2024	Nantahala Capital Management, LLC	added	111	1,138,800	1,819,150	0.05%
Feb 14, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
Feb 14, 2024	CANTOR FITZGERALD, L. P.	added	1.00	3,079,580	3,488,480	0.72%
Feb 14, 2024	TANG CAPITAL MANAGEMENT LLC	unchanged	-	30,225	143,325	0.01%

Are Funds Buying or Selling ACRX?

Are funds buying ACRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ACRX

No. of Funds

Unveiling AcelRx Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	4.99%	890,346	SC 13G/A
Feb 13, 2024	lind global fund ii lp	4.2%	735,296	SC 13G/A
Jan 23, 2024	nantahala capital management, llc	11.8%	1,992,519	SC 13D
Aug 01, 2023	lind global fund ii lp	6.5%	1,102,944	SC 13G
Feb 14, 2023	armistice capital, llc	9.99%	864,328	SC 13G/A
Feb 15, 2022	armistice capital, llc	9.99%	12,314,479	SC 13G
Jan 27, 2022	bml investment partners, l.p.	0.0%	0	SC 13G/A
Jul 12, 2021	blackrock inc.	1.9%	2,266,040	SC 13G/A
Feb 10, 2021	bml investment partners, l.p.	5.3%	5,200,000	SC 13G/A
Jan 29, 2021	blackrock inc.	5.7%	5,640,946	SC 13G/A

Recent SEC filings of AcelRx Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 19, 2024	8-K	Current Report
Mar 21, 2024	4	Insider Trading
Mar 15, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading
Mar 06, 2024	10-K	Annual Report
Mar 06, 2024	8-K	Current Report
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading

Peers (Alternatives to AcelRx Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	357.8B	85.2B	-4.29%	-10.06%	10.18	4.2	6.46%	95.94%
MRK	321.7B	60.1B	1.36%	9.00%	881.36	5.35	1.40%	-97.49%
PFE	148.3B	46.5B	-4.27%	-33.23%	-106.79	3.19	42.59%	-114.62%
AMGN	146.3B	28.2B	-2.78%	11.49%	21.78	5.19	7.09%	2.52%
GILD	83.6B	27.1B	-7.58%	-21.63%	14.75	3.08	-0.60%	23.36%
TEVA	14.6B	15.8B	-7.47%	58.08%	-25.3	0.92	6.17%	76.47%
MID-CAP
PRGO	4.2B	4.7B	0.71%	-13.71%	-333.24	0.91	4.58%	90.97%
ALKS	4.1B	1.7B	-9.74%	-19.21%	11.58	2.48	49.61%	324.78%
BHC	3.1B	8.8B	-9.70%	20.22%	-5.28	0.36	7.79%	-163.11%
AMPH	2.0B	644.4M	-6.03%	4.38%	14.34	3.06	29.14%	50.51%
SMALL-CAP
TLRY	1.4B	743.2M	-14.42%	-17.86%	-4.05	1.92	24.65%	80.36%
TXMD	22.3M	1.3M	-15.72%	-46.54%	-2.17	17.09	-98.14%	-109.18%
ACRX	16.3M	-	-17.24%	40.47%	-0.89	0.22	2882.68%	-138.52%
AGRX	2.7M	19.6M	-33.33%	-94.15%	-0.19	0.14	80.00%	43.08%
ACOR	683.2K	117.6M	-96.48%	-95.45%	0	0.01	-0.79%	-283.60%

AcelRx Pharmaceuticals Inc News

Latest updates

AcelRx Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	-100.0%	-	5,511,000	-	-	84,052,000	42,027,000	2,000	1,862,000	443,000	511,000	738,000	1,368,000	2,924,000	386,000	294,000	608,000	941,000	627,000	613,000	377,000	818,000
Costs and Expenses	-14.3%	4,564,000	5,328,000	5,886,000	4,523,000	9,955,000	4,936,000	-12,112,000	10,495,000	10,458,000	9,653,000	9,982,000	10,405,000	9,758,000	16,234,000	15,467,000	14,142,000	14,302,000	12,583,000	11,590,000	9,705,000	7,971,000
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11,590,000	9,705,000	7,971,000
S&GA Expenses	-34.7%	2,795,000	4,281,000	5,227,000	3,724,000	3,960,000	4,100,000	-9,490,000	8,640,000	8,694,000	7,644,000	7,846,000	7,598,000	7,575,000	13,311,000	12,786,000	10,936,000	11,329,000	9,976,000	7,648,000	5,188,000	3,944,000
R&D Expenses	69.0%	1,769,000	1,047,000	612,000	799,000	1,094,000	836,000	-674,000	1,416,000	724,000	969,000	836,000	956,000	813,000	1,412,000	1,063,000	1,058,000	1,163,000	1,377,000	2,704,000	3,642,000	3,278,000
EBITDA Margin	-100.0%	-	0.73	0.74	-0.22	-0.32	-0.57	-4.61	-10.10	-11.64	-6.40	-6.50	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-100.0%	-	119,000	188,000	245,000	293,000	390,000	369,000	538,000	614,000	672,000	754,000	824,000	872,000	855,000	831,000	828,000	500,000	376,000	459,000	529,000	586,000
Income Taxes	-Infinity%	-5,000	-	-1,000	11,000	3,000	-	-	-	5,000	-	-	-	4,000	-	-	-	3,000	-	-	-	2,000
Earnings Before Taxes	-	-	-	3,885,000	-6,739,000	70,666,000	-	10,030,000	-8,375,000	-9,846,000	-	-8,918,000	-8,930,000	-6,602,000	-	-14,423,000	-12,731,000	-12,409,000	-	-12,558,000	-12,458,000	-10,539,000
EBT Margin	-100.0%	-	0.70	0.70	-0.27	-0.39	-0.74	-6.08	-11.36	-13.19	-7.29	-7.45	-	-	-	-	-	-	-	-	-	-
Net Income	44.6%	-4,517,000	-8,152,000	-7,484,000	-6,750,000	70,663,000	-8,674,000	-7,917,000	-8,375,000	-9,851,000	-8,956,000	-8,918,000	-8,930,000	-6,606,000	-15,925,000	-14,423,000	-12,731,000	-12,412,000	-13,674,000	-12,558,000	-12,458,000	-10,541,000
Net Income Margin	-100.0%	-	0.57	0.57	0.74	1.05	-1.51	-12.46	-10.16	-11.98	-6.03	-7.46	-	-	-	-	-	-	-	-	-	-
Free Cashflow	26.2%	-3,949,000	-5,350,000	-5,461,000	-5,396,000	-8,815,000	-9,023,000	-8,032,000	-4,127,000	-9,938,000	-9,732,000	-7,958,000	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-12.3%	20.00	23.00	18.00	26.00	47.00	48.00	56.00	72.00	78.00	72.00	80.00	87.00	66.00	66.00	67.00	77.00	91.00	105	115	113	121
Current Assets	-19.9%	12.00	14.00	9.00	17.00	25.00	25.00	32.00	43.00	50.00	52.00	59.00	71.00	47.00	48.00	49.00	58.00	72.00	86.00	97.00	95.00	108
Cash Equivalents	-57.3%	6.00	13.00	7.00	13.00	15.00	13.00	15.00	22.00	8.00	8.00	21.00	34.00	22.00	20.00	22.00	24.00	15.00	22.00	65.00	73.00	88.00
Inventory	-	-	-	-	-	1.00	1.00	1.00	1.00	1.00	2.00	1.00	1.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	2.00	1.00
Net PPE	-	-	-	-	-	-	11.00	11.00	16.00	5.00	16.00	16.00	16.00	16.00	14.00	14.00	15.00	15.00	14.00	13.00	12.00	11.00
Liabilities	27.0%	6.00	5.00	7.00	12.00	26.00	21.00	23.00	110	114	115	116	115	122	124	128	133	133	133	134	121	116
Current Liabilities	26.2%	5.00	4.00	4.00	9.00	14.00	16.00	18.00	17.00	19.00	17.00	15.00	16.00	18.00	17.00	16.00	16.00	14.00	11.00	8.00	19.00	16.00
Long Term Debt	-	-	-	-	-	-	-	-	3.00	5.00	7.00	9.00	11.00	13.00	15.00	17.00	19.00	21.00	22.00	24.00	-	3.00
LT Debt, Current	-	-	-	-	3.00	5.00	8.00	10.00	9.00	8.00	9.00	9.00	9.00	9.00	9.00	9.00	7.00	5.00	2.00	-	10.00	9.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	3.00	5.00	7.00	9.00	11.00	13.00	15.00	17.00	19.00	21.00	22.00	24.00	-	3.00
Shareholder's Equity	-23.0%	14.00	18.00	10.00	14.00	22.00	27.00	33.00	-	-35.89	-	-	-	-	-	-	-	-	-	-	-	4.00
Retained Earnings	-1.0%	-444	-439	-438	-433	-425	-418	-411	-482	-473	-465	-457	-447	-438	-429	-420	-414	-398	-383	-370	-358	-345
Additional Paid-In Capital	0.1%	458	458	449	448	448	446	445	444	438	423	421	420	383	372	360	359	357	355	352	351	349
Shares Outstanding	0.0%	17.00	17.00	11.00	11.00	8.00	7.00	7.00	7.00	7.00	6.00	6.00	6.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	12.00	-	-	-	36.00	-	-	-	161	-	-	-	95.00	-	-	-	197	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-33.4%	-3,949	-2,960	-5,333	-5,250	-5,413	-5,238	-8,746	-8,934	-8,004	-3,943	-8,347	-9,708	-6,327	-8,124	-9,690	-14,364	-14,155	-11,466	-12,319	-13,240	-8,990
Share Based Compensation	-17.7%	311	378	471	569	652	701	753	783	1,127	1,221	1,172	1,089	1,084	1,104	1,090	1,146	1,278	1,326	1,346	1,107	1,232
Cashflow From Investing	-Infinity%	-3,651	-	2,723	400	2,660	4,442	9,172	20,176	-4,439	-6,652	2,393	-17,425	5,775	-1,214	6,928	22,650	6,889	-33,206	-10,617	371	-11,960
Cashflow From Financing	-100.8%	-68.00	8,939	-3,333	-2,072	5,296	-1,637	-2,083	-2,083	11,835	-2,461	-2,082	34,222	7,853	7,522	665	916	1.00	1,550	14,695	-1,794	51,359

ACRX Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Total revenue	$ 651	$ 0
us-gaap_OperatingCostsAndExpensesAbstract
Research and development	5,546	3,341
Selling, general and administrative	11,994	17,011
Impairment of property and equipment	0	4,948
Total operating costs and expenses	17,540	25,300
Loss from operations	(16,889)	(25,300)
Interest expense	(134)	(1,116)
Interest income and other income, net	6,736	366
Non-cash interest income on liability related to sale of future royalties	0	1,136
Non-cash gain on extinguishment of liability related to the sale of future royalties	0	84,052
Total other income, net	6,602	84,438
Net income (loss) before provision for income taxes	(10,287)	59,138
Provision for income taxes	0	(13)
Net (loss) income from continuing operations	(10,287)	59,125
Net loss from discontinued operations – See Note 3	(8,110)	(11,370)
Net income (loss)	(18,397)	47,755
Deemed dividend related to Series A Redeemable Convertible Preferred Stock	0	(186)
Income allocated to participating securities	0	(5,240)
Net income (loss) attributable to Common Shareholders, basic	(18,397)	42,329
Net income (loss) attributable to Common Shareholders, diluted	$ (18,397)	$ 42,342
us-gaap_EarningsPerShareBasicAbstract
(Loss) income from continuing operations (in dollars per share)	$ (0.72)	$ 7.27
Loss from discontinued operations (in dollars per share)	(0.57)	(1.54)
Net income (loss) per share of common stock, basic (in dollars per share)	(1.29)	5.73
us-gaap_EarningsPerShareDilutedAbstract
(Loss) income from continuing operations (in dollars per share)	(0.72)	7.25
Loss from discontinued operations (in dollars per share)	(0.57)	(1.53)
Net (loss) income per share (in dollars per share)	$ (1.29)	$ 5.72
Shares used in computing net (loss) income per share of common stock, basic – See Note 12 (in shares)	14,263,744	7,385,348
Shares used in computing net (loss) income per share of common stock, diluted – See Note 12 (in shares)	14,263,744	7,406,986

ACRX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 5,721	$ 15,275
Restricted cash	0	5,000
Short-term investments	3,660	495
Prepaid expenses and other current assets	2,175	1,865
Assets of discontinued operations	0	1,931
Total current assets	11,556	24,566
In-process research and development asset	8,819	8,819
Other assets	20	166
Assets of discontinued operations	0	13,936
Total assets	20,395	47,487
Current Liabilities:
Accounts payable	1,336	1,256
Accrued and other liabilities	2,445	2,531
Long-term debt, current portion	0	5,363
Liabilities of discontinued operations, current portion	731	4,620
Total current liabilities	4,512	13,770
Warrant liability	1,778	7,098
Other long-term liabilities	0	810
Liabilities of discontinued operations	0	3,995
Total liabilities	6,290	25,673
Commitments and Contingencies
us-gaap_StockholdersEquityAbstract
Common stock, $0.001 par value—200,000,000 shares authorized as of December 31, 2023 and 2022; 16,952,519 and 8,243,680 shares issued and outstanding as of December 31, 2023 and 2022, respectively	17	8
Additional paid-in capital	458,314	447,635
Accumulated deficit	(444,226)	(425,829)
Total stockholders’ equity	14,105	21,814
Total Liabilities and Stockholders’ Equity	$ 20,395	$ 47,487

About AcelRx Pharmaceuticals Inc

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.

CEO	Mr. Vincent J. Angotti
WEBSITE	acelrx.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	19